HCAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Health Catalyst Inc (HCAT) is not a good buy for a beginner investor with a long-term horizon at this time. The company's financial performance is weak, analysts have downgraded the stock with reduced price targets, and insiders are heavily selling. While there is a slight positive technical momentum, the lack of strong positive catalysts and the absence of Intellectia Proprietary Trading Signals make this stock unsuitable for investment currently.
The MACD histogram is positive at 0.0423, indicating slight bullish momentum. However, the RSI is neutral at 71.489, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 1.276), suggesting limited upside potential in the short term.
NULL significant. The MACD indicates slight bullish momentum, and there is a 70% chance of a small price increase in the next month.
Insiders are selling heavily, with an 869.22% increase in selling activity over the last month. The company is undergoing strategic and operational reviews, which adds uncertainty.
In Q4 2025, revenue declined by -6.19% YoY to $74.68 million. Net income improved but remains negative at -$91.03 million. EPS increased but is still negative at -1.28. Gross margin improved to 35.48%, up 15.42% YoY, but overall financial performance remains weak.
Analysts have downgraded the stock and lowered price targets significantly. Wells Fargo downgraded the stock to Equal Weight with a price target of $1, citing persistent revenue and margin pressures. Other firms have also reduced price targets, with most maintaining Neutral or Hold ratings. Analysts are cautious about the company's ongoing strategic and operational reviews.
